The Newswire for Business Lawyers

Merck's Fosamax May Boost Cancer Risk: FDA Official

Law360, New York (January 05, 2009) -- In the latest blow to Merck & Co. Inc. over Fosamax, a U.S. Food and Drug Administration official has said the popular osteoporosis treatment and other similar drugs may increase the risk of developing esophageal cancer.

Diane Wysowski of the FDA's division of drug risk assessment said in a letter published Thursday in the New England Journal of Medicine that the potential links should be explored...

Login

E-mail
Password
 
  I forgot my login details.

For the whole story, take a 7-day free trial.

Submit your request to try Law360 for free for seven days:

*
*
*
*
*
*
*
*

*Required

Select at least one interest area:*
You will receive Law360's free daily newsletter for the interest area(s) selected..

Appellate
Bankruptcy
Competition
Contract
Corporate Finance
Employment
Energy
Environmental
Financial Services
Health
Insurance
Intellectual Property
International Trade
Product Liability
Securities
Technology
Top News (General Interest)
The only daily news service covering every major practice area of the law.
  • Breaking news available nowhere else
  • More than 66% of articles published before or simultaneously with any other source
  • 63% of articles have critical legal documents attached
  • More than 1,000 columns by leading practitioners published per year
  • More than 20,000 exclusive articles published per year
  • Detailed coverage of 16 major practice areas